ARM, EFPIA, EUCOPE, EuropaBio, Vaccines Europe From 12 January 2025 the Regulation (EU) 2021/2282 on health technology assessment will apply and the first Joint Clinical Assessments (JCA) will be performed to assess the relative clinical effectiveness of new innovative cancer therapies and cell and gene… read more
A new college of Commissioners All signs point towards the need for a more competitive environment for pharmaceutical R&D in Europe. In this context, EUCOPE extends its congratulations to the newly appointed European Commissioners, whose mandates will deliver on large-scale change initiated under the last… read more
Brussels, 15 November 2023 Today, EUCOPE and FTI Consulting EU published a report titled The Economic Lens: Understanding What Makes the EU Attractive for Life Sciences Investments. The report provides an analysis of the current environment in the EU for attracting life sciences investments and… read more
On Tuesday 24 September, Alexander Natz, Secretary General of the European Confederation of Pharmaceuticals Entrepreneurs (EUCOPE), sent a letter to the President of the European Commission Ursula von der Leyen, President of the European Parliament Roberta Metsola, and President of the European Council Charles Michel,… read more
The European Confederation of Pharmaceuticals Entrepreneurs (EUCOPE) announced the joining of 7 new members at its quarterly Members Meeting on 18 June 2024, following Board approval. The new members joining the EUCOPE network are Acadia, Edelman Global Advisory, Elevate Bio, GE Healthcare, Regeneron, Rhythm Pharmaceuticals and… read more
At the Employment, Social Policy, Health and Consumer Affairs Council (EPSCO) meeting on 21 June, Health Ministers adopted Council Conclusions on the Future of the European Health Union. Presenting the Council’s perspective on the forthcoming EU health agenda, the Conclusions outline strategic priorities and actions… read more
The European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) extends its heartfelt congratulations to the newly elected Members of the European Parliament (MEPs). As the key representative body for predominantly small and medium-sized innovative pharmaceutical companies in Europe, EUCOPE recognises the pivotal role MEPs play in shaping… read more
The Regulation on Substances of Human Origin (SoHO) has been officially adopted by the EU Institutions, following the European Parliament’s approval on 24 April and the formal adoption by the Council of the European Union on 27 May. The new Regulation aims to improve the… read more
In June 2024, the Cancer Patients Europe, the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE), the European Society of Pathology and Lung Cancer Europe (LuCE) published a joint statement on increasing access to genomic testing, delivering on the ambitions of Europe’s Beating Cancer Plan. Over the past 10 years,… read more
On 16 May 2024, EUCOPE signed EURORDIS Open Letter #ActRare2024, during the Closing Plenary session of the 12th European Conference on Rare Diseases and Orphan Products (ECRD), organised in Brussels on 15-16 May 2024. The Open Letter is a result of, and informed by, the… read more
Keep up-to-date on all of the most pertinent policy files and regulatory news around the world of European health technologies with our monthly newsletter – the Innovation Eye-View
You are currently viewing a placeholder content from Facebook. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
You are currently viewing a placeholder content from Instagram. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
You are currently viewing a placeholder content from X. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
